Literature DB >> 15644433

Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists.

Davide Pau1, Antony J Workman, Kathleen A Kane, Andrew C Rankin.   

Abstract

Prucalopride is a selective 5-hydroxytryptamine type 4 (5-HT4) receptor agonist developed for the treatment of gastrointestinal disorders. The endogenous agonist 5-HT acting via 5-HT4 receptors increases the L-type Ca2+ current (I(CaL)) with potentially proarrhythmic consequences (Pau et al., 2003). The aims of this study were to investigate the effects of prucalopride on I(CaL), action potentials, refractory period, and arrhythmic activity in human atrial myocytes, and to compare these with the effects of 5-HT, using the whole-cell perforated patch-clamp technique. Prucalopride (10(-9) to 10(-4) M) produced a concentration-dependent increase in I(CaL) amplitude, with a maximum response at 10 microM, from -5.3 +/- 0.6 to -10.9 +/- 1.5 pA/pF (p < 0.05; n = 22 cells, 10 patients), without affecting its voltage-dependence. Subsequent application of 10 microM 5-HT further increased I(CaL) to -17.7 +/- 2.8 pA/pF (p < 0.05; n = 16 cells, 9 patients). The increase in I(CaL) by prucalopride, 98 +/- 15%, was significantly smaller than that by 5-HT, 233 +/- 26% (p < 0.05). Prucalopride (10 microM) significantly increased the action potential duration at 50% repolarization (APD50) from 12 +/- 2 to 17 +/- 3 ms (p < 0.05; n = 22 cells, 9 patients). Following washout of prucalopride, 5-HT (10 microM) increased APD50, to a greater extent, from 14 +/- 3 to 32 +/- 7 ms (p < 0.05; n = 11 cells; 8 patients). The APD75, APD90, and effective refractory period were unaffected by prucalopride or 5-HT. Furthermore, 5-HT induced abnormal depolarizations in 27% of the cells studied, whereas prucalopride induced none (p < 0.05). In conclusion, in human atrial cells, prucalopride, at concentrations markedly above those used therapeutically, acted as partial agonist on I(CaL) and APD50, with no effect on late repolarization or refractory period, and was devoid of arrhythmic activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644433     DOI: 10.1124/jpet.104.076869

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  An update on prucalopride in the treatment of chronic constipation.

Authors:  Anam Omer; Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2017-10-16       Impact factor: 4.409

2.  Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic mice.

Authors:  Nicolas Keller; Stefan Dhein; Joachim Neumann; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-09       Impact factor: 3.000

3.  Role of cAMP/PKA pathway and T-type calcium channels in the mechanism of action of serotonin in human adrenocortical cells.

Authors:  Estelle Louiset; Céline Duparc; Sébastien Lenglet; Celso E Gomez-Sanchez; Hervé Lefebvre
Journal:  Mol Cell Endocrinol       Date:  2016-10-12       Impact factor: 4.102

4.  Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants.

Authors:  Kurt A Krobert; Trond Brattelid; Finn Olav Levy; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

5.  Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development.

Authors:  Joris H De Maeyer; Roel Straetemans; Jan A J Schuurkes; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 6.  Prucalopride: A Review in Chronic Idiopathic Constipation.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

Review 7.  Prucalopride: a review of its use in the management of chronic constipation.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

8.  Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.

Authors:  Banny S Wong; Noriaki Manabe; Michael Camilleri
Journal:  Clin Exp Gastroenterol       Date:  2010-05-24

9.  Electrophysiological and arrhythmogenic effects of 5-hydroxytryptamine on human atrial cells are reduced in atrial fibrillation.

Authors:  Davide Pau; Antony J Workman; Kathleen A Kane; Andrew C Rankin
Journal:  J Mol Cell Cardiol       Date:  2006-09-20       Impact factor: 5.000

10.  From ionic to cellular variability in human atrial myocytes: an integrative computational and experimental study.

Authors:  Anna Muszkiewicz; Xing Liu; Alfonso Bueno-Orovio; Brodie A J Lawson; Kevin Burrage; Barbara Casadei; Blanca Rodriguez
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-22       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.